Grafalon Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Rabbit anti-human T-lymphocyte Ig

Indications/Uses

In combination w/ other immunosuppressive medicinal products for the suppression of immune competent cells, which are the cause for acute rejection. In combination w/ other immunosuppressive medicinal products (eg, glucocorticosteroids, purine antagonists, calcineurin inhibitors or mTOR inhibitors) for the prevention of acute transplant rejections in patients receiving allogeneic solid organ transplants. Acute corticosteroid-resistant rejection after allogeneic solid organ transplantation.

Dosage/Direction for Use

IV Prevention of acute transplant rejection in patients receiving allogeneic solid organ transplants 2-5 mg/kg daily for 5-14 days depending on the patient's condition, selected daily dose & concomitant immunosuppressive regimen. Commence therapy on the day of transplantation pre-, intra-, or immediately post-op. Acute corticosteroid-resistant rejection after allogeneic solid organ transplantation 3-5 mg/kg daily for 5-14 days depending on the condition of grafted organ & clinical response.

Contraindications

Hypersensitivity. Patients w/ bacterial, viral, parasitic or mycotic infection which are not under adequate therapeutic control & those w/ malignant tumors except in cases where stem cell transplantation is performed as part of treatment. Solid organ transplant patients w/ severe thrombocytopenia (eg, <50,000 platelets/μL).

MIMS Class

Immunosuppressants

ATC Classification

L04AA04 - antithymocyte immunoglobulin (rabbit) ; Belongs to the class of selective immunosuppressive agents. Used to induce immunosuppression.

Regulatory Classification

POM

Presentation/Packing

Form

Grafalon 20 mg per 1 mL infusion conc

Packing/Price

1's

Grafalon

Manufacturer:

Neovii Biotech